Compare Annaly Capital Management, Inc. (NLY) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Annaly Capital Management, Inc. vs State Street SPDR S&P Biotech ETF — how do they compare? Annaly Capital Management, Inc. trades at $22.79 (market cap $17.04B), while State Street SPDR S&P Biotech ETF trades at $159.85. The key difference: Annaly Capital Management, Inc. pays a 13.27% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Annaly Capital Management, Inc. nearer its low. Which is the better fit depends on your goals.
| NLY | XBI | |
|---|---|---|
Market Cap | $17.04B | — |
Sector | Financials | Broad Market / Factor |
52-Week High | $24.40 | $169.55 |
52-Week Low | $20.21 | $93.43 |
Dividend Yield | 13.27% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Annaly Capital Management (NLY) trades at $22.72, down 0.39% for the day, with a bearish technical signal from moving averages but oversold RSI readings. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $0.79 exceeding the $0.751 estimate. Fundamentals show a high net income margin of 92.77% and a return on equity of 20.66%, though cash flow from operations declined to $692.91 million in 2025. Recent news includes a declared $0.75 dividend and a preferred stock redemption.
The outlook for NLY is supported by analyst consensus with a $24.33 price target and a majority buy rating, indicating potential upside. However, risks include significant investing cash outflows, high leverage with debt-to-asset ratio rising to 23.55 in 2025, and sensitivity to interest rate changes. The stock offers a high dividend yield but faces headwinds from mortgage rate volatility and tax inefficiencies for investors in taxable accounts.
XBI trades at $161.97, down 1.12% today, with technical indicators showing mixed signals amid a bearish overall trend. The ETF holds over 150 biotech companies and has rallied 76% in the past year, driven by M&A activity and positive clinical trial catalysts. Analyst coverage remains limited with a single hold rating, while recent news highlights sector optimism around cancer vaccine breakthroughs and improved capital access.
Outlook remains cautiously optimistic with potential for 8-14% returns over 6-12 months, though high volatility and regulatory risks persist. Key opportunities include ongoing pharmaceutical M&A and innovation in immunotherapy, while risks center on sector-specific volatility and policy uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Annaly Capital Management, Inc.
Annaly Capital Management Inc is an American mortgage real estate investment trust. The company segments its operations into Residential and Commercial real estate investments. While Annaly's Residential assets are primarily comprised of agency mortgage-backed securities and debentures, it is primarily invested in commercial mortgage loans and mortgage-backed securities in its Commercial unit through its subsidiary, Annaly Commercial Real Estate Group. Agency mortgage-backed securities and debentures make up the majority of the company's overall portfolio. Most of the company's counterparties are located in the U.S. Annaly generates nearly all of its revenue from the spread between interest earned on its assets and interest payments made on its borrowings.
Read more on NLY →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
